Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013991 | 0.86 | RAB9A (0.67) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL6672199 | 0.84 | RAB9A (0.65) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL19651320 | 0.81 | NPC1 (0.62) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL2513223 | 0.80 | CCNE1 (0.53) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL2511636 | 0.79 | CCNE1 (0.52) | ALDH1A1RAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL14568924 | 0.78 | LCK (0.73) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3580881 | 0.77 | POLB (0.63) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL4605012 | 0.76 | ALDH1A1 (0.69) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL773361 | 0.74 | LCK (0.59) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL5607979 | 0.74 | RAB9A (0.56) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | ALDH1A1 906/4885RAB9A 2140/4885NPC1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.